Sector Update: Health Care Stocks Advance Wednesday Afternoon

MT Newswires11/21 03:00

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Accesswire11/20 21:35

Aptevo Therapeutics And Alligator Bioscience's Bispecific Antibody ALG.APV-527 Meets Key Endpoints In Phase 1 Solid Tumor Trial; Shows Favorable Safety And Immune Activation With Stable Disease In Colon And Breast Cancer Patients

Benzinga11/11 21:07

Aptevo Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.

Benzinga11/08 01:44

10-Q：Q3 2024 四半期報告書

SEC11/07 21:33

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Accesswire11/07 21:05